ChromaDex Delivers Strong Q1 2010 Financial Results

IRVINE, Calif., May 18 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the first quarter of 2010.

In the first quarter of fiscal 2010, ChromaDex recorded revenue during the first quarter of 2010 of $1,937,592 as compared to $1,447,127 for the same period in 2009.  This represents a 34 percent year-over-year revenue growth.

On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net income attributable to common stockholders of less than $0.01 per share for the thirteen week period ended April 3, 2010.

"With the launch of pTeroPure and the growth of our core business, we are in an ideal position to be the partner of choice for food, beverage, dietary supplement, and cosmetic companies as they look to strengthen their respective businesses through new product offerings and improved product quality," said Frank Jaksch, CEO and co-founder of ChromaDex.

Additional Financial Results & Notes

On a reported basis, the net income attributable to common stockholders for the thirteen weeks ended April 3, 2010, was $33,742 as compared to a net loss of $323,842 for the same period in 2009. The net income in the first quarter is attributable to the increase in revenues coupled with a decrease in direct labor and overhead as a percentage of sales.  As of April 3, 2010, cash, cash equivalents, and marketable securities totaled $538,675.

About ChromaDex

ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure™ pterostilbene (www.pteropure.com) as a result of its exclusive worldwide patent rights for pterostilbene. For more information, visit www.chromadex.com or follow ChromaDex on Twitter @ChromaDex.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

SOURCE ChromaDex Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED